Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Long intergenic non-protein coding RNA 2167 (LINC02167)** is a long non-coding RNA (lncRNA) located in intergenic genomic regions, meaning it does not encode a protein. It is significantly upregulated in colorectal cancer tissues and is associated with advanced clinical features and poor prognosis. Functionally, LINC02167 is predominantly cytoplasmic and acts as a molecular scaffold, forming complexes with RNA-binding proteins YBX1 and ILF3 to stabilize KSR1 mRNA through NSUN2-mediated 5-methylcytosine (m5C) modification, thereby enhancing ERK/MAPK pathway signaling and promoting cancer cell migration, invasion, and metastasis. Myc-driven transcription acts upstream to upregulate its expression in cancer. LINC02167 is considered a promising therapeutic target in metastatic colorectal cancer, although no approved drugs currently target it directly[1][2].
RNA-mediated scaffolding of RNA-binding proteins (YBX1, ILF3) to promote KSR1 mRNA stability; Positive regulation of ERK/MAPK pathway signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2167 (LINC02167).